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To investigate the influence of vascular normalization on solid tumor blood perfusion and
drug delivery, we used the generated blood vessel network for simulations. Considering the
hemodynamic parameters changing after antiangiogenic therapies, the results show that the
interstitial fluid pressure IFP in tumor tissue domain decreases while the pressure gradient
increases during the normalization window. The decreased IFP results in more eﬃcient delivery
of conventional drugs to the targeted cancer cells. The outcome of therapies will improve if the
antiangiogenic therapies and conventional therapies are carefully scheduled.
1. Introduction
Angiogenesis, the growth of a network of blood vessels, plays a significant role in tumor’s
growth, invasion, and metastasis. Therefore, blocking angiogenesis could be a strategy
for arresting tumor growth 1. As the features of angiogenesis inhibitors are of low
toxicity and have less acquired resistance, it comes to a new strategy to suppress tumor
growth by restraining angiogenesis. The widely held view is that the antiangiogenic
therapies can destroy the tumor vasculature, thereby depriving the tumor of oxygen and
nutrients. When administered as single agents, antiangiogenic therapies have produced
modest objective responses in clinical trials, but they have not obtained a long-term eﬀect.
However, several preclinical and clinical studies have shown that antiangiogenic therapies
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Figure 1: Proposed eﬀect of drug dose and schedule on tumor vasculature normalization window 2.
improve the outcome of cytotoxic therapies. This is paradoxical. Based on that, Jain 2
proposed a new hypothesis that the antiangiogenic therapies can transiently “normalize” the
abnormal structure and function of tumor vascular and microenvironment Figure 1. There
is a “vasculature normalization window” during antiangiogenic therapy. This view has been
supported by clinical data.
The vasculature of solid tumors is structurally and functionally diﬀerent from normal
blood vessels 3. They are leaky, tortuous, dilated, and saccular. Branches are irregular, and
vessel diameters are uneven. In addition, the vessel wall has abnormal structure. The endo-
thelial cells have aberrant morphology. They are loosely attached, and usually there are gaps.
The basement membrane has diverse thickness with broken or missing pieces.
In normal tissues, interstitial fluid pressure IFP is close to zero; however, IFP is
elevated in tumors in patients. The high IFP poses a strong barrier to the delivery of drugs
into tumors and interstitium 4. There are two other characteristics of the abnormal tumor
microenvironment—hypoxia and acidosis 5–7. One of the main functions of vasculature
system is to provide cells with nutrition and oxygen and take away the waste of metabolism
at the same time. However, tumor vasculature does not have the same function. Hypoxia
renders tumor cells resistant to both radiation and cytotoxic drugs. Meanwhile, the low PH
value hindered the eﬃcacy of therapies.
Above all of these show that if we could find a way to fix the abnormal tumor vascu-
lature and microenvironment, we would improve the treatment of cancer. Jain 8 showed
that antiangiogenic therapy could cause a transient “vascular normalization window” and
decrease IFP by changing the tumor sizes, vascular hydraulic permeability, and/or the
surface area per unit tissue volume of tumor vessels. Normalization of tumor vasculature
andmicroenvironment results in more eﬃcient delivery of conventional drugs to the targeted
cancer cells. The outcome of therapies will improve if the antiangiogenic therapies and con-
ventional therapies are carefully scheduled.
In recent years, several mathematical models used diﬀerent approaches to improve the
understanding of tumor hemodynamics. McDougall et al. 2002 9 built a two-dimensional
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Figure 2: The vasculature for flow simulations; the blue lines on top and bottom of lattice represent the
parent vessels, and the big red circle represents the tumor domain. a The tumor vasculature without
antiangiogenesis therapy; b the tumor vasculature under antiangiogenesis therapy.
capillary network model to study nutrition, oxygen, and drugs transport to the tumor. Tee
et al. 2004 10 created a discrete model to simulate the drug delivery mode under endos-
tatin and the eﬀect on tumor angiogenesis caused by drug clearance. Our research group has
done some related work. Gaiping et al. 2006 11 built the network model under Endostatin
using random discretemethods. Wu et al. 2009 12 simulated tumor blood perfusion based
on 3D angiogenic microvasculature. Here, we use 2D microvasculature built by the group
before and simulate the blood perfusion and drug delivery during vasculature normalization.
2. Blood Perfusion during the “Vasculature Normalization Window”
We employ a mathematical model to show the eﬀect of the kinetic parameters on tumor blood
perfusion; detailed equations and numerical methods can be seen in 12.
In this paper, we used the vascular network generated by our group for the simulation,
shown in Figure 2. The actual size is 4mm × 4mm, divided into 200 × 200 equally spaced
grids. Tumor was located in the center of the region, with a radius of 1mm. The surrounding
is normal tissue, and two parent vessels are in the upper and lower bounds, respectively.
During the “vascular normalization window,” several parameter values of microen-
vironment become close to normal tissues 13–16, such as Lp, KP , S/V , σπν − πi, and
R. Here, Lp is the vascular wall permeability cm/mmHgs, KP is the interstitial hydraulic
conductivity cm2/mmHgs, S/V is the surface area of vessel wall per unit volume of tissue
cm−1, σπν − πi is oncotic pressure mmHg, and R is the tumor radius. Our analysis
suggests, however, that σπν−πi is much smaller than the value of normal tissues, even after
antiangiogenic therapies. Consequently, oncotic pressure dose not significantly influence the
tumor blood perfusion.
The simulation results are shown in Figure 3. We show here that vascular normal-
ization can decrease tumor IFP in a number of ways. The maximum value of IFP dropped
from 11.87mmHg to 4.06mmHg. Furthermore, the phenomenon of high interstitial pressure
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Figure 3: The simulation results of blood perfusion. Pi is the interstitial fluid pressure IFP.
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Figure 4: The simulation result of drug concentration before treatment.
gradient has been greatly improved, except that the boundary of the tumor still has a slightly
higher pressure gradient. All of these will benefit the drug delivery and the outcome of con-
ventional therapies.
3. Drug Delivery during Vascular Normalization
3.1. Mathematical Model
Drugs enter the circulatory system of human body and transport to the tumor microcir-
culation. To balance the plasma drug concentration is related to the systemic circulation.
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Figure 5: The simulation result of drug concentration after treatment.
Compared with the scale of the human body, the tumor is small. Therefore, the influence on
plasma drug concentration reaching stable state can be neglected. In our model, drugs enter
the interstitium through capillary walls. A part of the drugs in the interstitium are absorbed
by lymphatic vessels as well as cleared by certain organs. The average drug concentrations in
plasma CP  and in interstitium Ce are represented by the following equations:
dCP t
dt
 −ke · CP t −K · CP 	 It,
dCet
dt
 K · Cpt − L · Cet.
3.1
ke denotes drug clearance. K and L are transport coeﬃcients from the plasma to the
interstitium and from the interstitium to lymphatic vessels, respectively. It denotes the
amount of drugs injected into plasma:
It
⎧
⎨
⎩
1, t  0,
0, t > 0.
3.2
The initial conditions are given by
CP 0  0, Ce0  0. 3.3
After drugs enter the tumor, the interstitial flow influences the drug delivery as well as
the diﬀusion eﬀect. Here, we use the results of the blood perfusion descried before. Due to the
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Table 1: Baseline parameter values used for drug delivery simulations 19–21. Parameter values with
superscripts “T,” “N” represent the internal and external parameters of the tumor.
Parameter Value Parameter Value
kes−1 1.33 × 10−4 Peﬀ10−6 cm/s 1.91N
K10−10 cm3/s/M 1.566 14.9T
L10−9 cm3/s/M 1.138 D10−8 cm2/s 1.2N
β 0.1 4.4T
Ka10−4/M/s 0N Kd 0N
1.33T 1.51T
high IFP, the convection eﬀect in the tumor can be ignored 17. The concentration of drugs
dx, y, t in the tumor satisfies the diﬀusion equation
∂d
(
x, y, t
)
∂t
	∇ ·
[
Rf
−→
U
(
x, y
)
d
(
x, y, t
)]
 ∇ · [D(x, y)∇d(x, y, t)]	φs
(
x, y, t
)−Ka · d
(
x, y, t
) · [A0−dB
(
x, y, t
)]
	Kd · dB
(
x, y, t
)
∂dB
(
x, y, t
)
∂t
 Ka · d
(
x, y, t
) · [A0 − dB
(
x, y, t
)] −Kd · dB
(
x, y, t
)
,
3.4
where Rf represents the relative velocity of drugs to the interstitial flow,
−→
Ux, y is the veloc-
ity distribution of the flow and can be gotten from
−→
U
(
x, y
)
 −KP · ∇Pi, 3.5
see 12. Dx, y denotes the diﬀusion coeﬃcient of drugs, dBx, y, t is the concentration
of antigen-binding drugs,Ka andKd represent the association rate and dissociation rate with
antigens, and φsx, y, t is the source term given by Kedem-Katchalsky equation 18
φs
(
x, y, t
)
 Γ
(
x, y
) · [Cpt − d
(
x, y, t
)] ·A. 3.6
Here, A represents the generated vessel network, and Γx, y is the permeability across the
capillary and is taken to be
Γ
(
x, y
)
 β · Peﬀ · S
V
, 3.7
where β is the corresponding coeﬃcient and Peﬀ denotes the eﬀective permeability coeﬃcient.
To solve the mathematical model, we use the FTBS method. The boundary condition
is set to be dx, y, t  0 when the point x, y is not in the computational domain. The initial
conditions are dx, y, 0  0 and dBx, y, 0  0.
The parameter values for simulation are in Table 1.
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4. Results and Discussion
In this paper, Figures 4 and 5 show the simulation results before and after antiangiogenic
therapies. We choose six time points to see the drug distribution within two days after the
injection. Figure 4 shows the uneven distribution of the concentration due to the blood vessel
network. The concentration in the blood-vessel-rich region is higher. There are almost no
vessels in the center, and the drug transports to this region only by diﬀusion. As a result, the
concentration is relatively low.Without supplement, the concentration decreases as time goes.
After four hours, the concentration gets smaller because of the drug clearance. Two days later,
there are almost no drugs at all. The concentration of drug in solid tumor can be meliorated
by normalization such as a lower IFP and a higher permeability. The drug delivery result
in Figure 5 is much better, not only the maximum but also the area of drug distribution.
Consequently it improves the outcome of chemotherapies.
In the paper, we ignore the change of the blood vessel network after antiangiogenic
therapies. As a matter of fact, the structure, number, and distribution of the vasculature
become diﬀerent during the “vascular normalization window.” In the further work, we will
consider the factor. Besides, the sensitivity analysis of the parameters will be considered, so
that we can elaborate on the eﬀect of each parameter on the results. To do that, a quantitative
measure should be defined to evaluate the eﬀect of the antiangiogenic therapies, for example,
the area covered by the drug.
The final goal of those combined therapies is to kill tumor cells, which makes it
important to study how the tumor grows after therapies. Besides, studies have shown that
antiangiogenesis-induced tumor cell starvationmay enhance chemotherapeutic drug activity,
despite a decrease in drug uptake. Balance can be found between them to improve the out-
come of therapies if both are carefully scheduled.
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